Skip to content

Medical Reference Related to Prostate Cancer

  1. Prostate Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Prostate Cancer Screening

    Tests are used to screen for different types of cancer.Some screening tests are used because they have been shown to be helpful both in finding cancers early and decreasing the chance of dying from these cancers. Other tests are used because they have been shown to find cancer in some people; however, it has not been proven in clinical trials that use of these tests will decrease the risk of dying from cancer. Scientists study screening tests to find those with the fewest risks and most benefits. Cancer screening trials also are meant to show whether early detection (finding cancer before it causes symptoms) decreases a person's chance of dying from the disease. For some types of cancer, finding and treating the disease at an early stage may result in a better chance of recovery.There is no standard or routine screening test for prostate cancer.Screening tests for prostate cancer are under study, and there are screening clinical trials taking place in many parts of the country.

  2. Prostate Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - About This PDQ Summary

    Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about prostate cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in

  3. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - About This PDQ Summary

    About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

  4. Prostate Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Evidence of Benefit

    Before the 1990s, the digital rectal examination (DRE) was the test traditionally used for prostate cancer screening. Two other procedures are also available: transrectal ultrasound (TRUS) imaging and serum prostate-specific antigen (PSA) concentrations.[1] Prostate cancer screening is controversial because of the lack of definitive evidence of benefit. A small randomized trial in Sweden evaluated the effects of screening men aged 50 to 69 years every 3 years; the first two screenings included DRE only, followed by two screenings with DRE combined with a test for PSA. The trial was not powered to detect even moderate differences in prostate cancer mortality, which was the same in the two groups: 1.3% (20 of 1,494 patients) for men assigned to screening and 1.3% (97 of 7,532 patients) for controls.[2] The controversy persists. A nested case-control study was conducted at ten U.S. Department of Veterans

  5. Prostate Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Risk Factors for Prostate Cancer Development

    AgeProstate cancer incidence escalates dramatically with increasing age. Although it is a very unusual disease in men younger than 50 years, rates increase exponentially thereafter. The registration rate by age cohort in England and Wales increased from eight per thousand population in men aged 50 to 56 years to 68 per thousand in men aged 60 to 64 years; 260 per thousand in men aged 70 to 74 years, and peaked at 406 per thousand in men aged 75 to 79 years.[1] In this same population, the death rate per thousand in 1992 in cohorts of men aged 50 to 54 years, 60 to 64 years, and 70 to 74 years was 4, 37, and 166, respectively.[1] At all ages, incidence of prostate cancer in blacks exceeds those of whites.[2]Family HistoryApproximately 15% of men with a diagnosis of prostate cancer will be found to have a first-degree male relative (e.g., brother, father) with prostate cancer, compared with approximately 8% of the U.S. population.[3] Approximately 9% of all prostate

  6. Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Prostate Cancer Treatment

    OverviewIn recurrent prostate cancer, the selection of further treatment depends on many factors, including:Previous treatment.Site of recurrence.Coexistent illnesses.Individual patient considerations. Definitive radiation therapy can be given to patients with disease that fails only locally following prostatectomy.[1,2,3,4] An occasional patient can be salvaged with prostatectomy after a local recurrence following definitive radiation therapy;[5] however, only about 10% of patients treated initially with radiation therapy will have local relapse only. In these patients, prolonged disease control is often possible with hormonal therapy, with median cancer-specific survival of 6 years after local failure.[6]Cryosurgical ablation of recurrence following radiation therapy is associated frequently with a high complication rate. This technique is still undergoing clinical evaluation.[7]Hormonal therapy is used to manage most relapsing patients with

  7. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Questions to Ask Your Health Care Provider About CAM

    When considering complementary and alternative therapies, patients should ask their health care provider the following questions: What side effects can be expected?What are the risks associated with this therapy?Do the known benefits outweigh the risks?What benefits can be expected from this therapy?Will the therapy interfere with conventional treatment?Is this therapy part of a clinical trial?If so, who is sponsoring the trial?Will the therapy be covered by health insurance?

  8. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - General CAM Information

    Complementary and alternative medicine (CAM)—also referred to as integrative medicine—includes a broad range of healing philosophies, approaches, and therapies. A therapy is generally called complementary when it is used in addition to conventional treatments; it is often called alternative when it is used instead of conventional treatment. (Conventional treatments are those that are widely accepted and practiced by the mainstream medical community.) Depending on how they are used, some therapies can be considered either complementary or alternative. Complementary and alternative therapies are used in an effort to prevent illness, reduce stress, prevent or reduce side effects and symptoms, or control or cure disease. Unlike conventional treatments for cancer, complementary and alternative therapies are often not covered by insurance companies. Patients should check with their insurance provider to find out about coverage for complementary and alternative therapies. Cancer patients

  9. Prostate Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage III Prostate Cancer Treatment

    OverviewStage III prostate cancer is defined by the American Joint Committee on Cancer's TNM classification system:[1]T3a–b, N0, M0, any prostate-specific antigen (PSA), any Gleason.Extraprostatic extension with microscopic bladder neck invasion (T4) is included with T3a.External-beam radiation therapy (EBRT), interstitial implantation of radioisotopes, and radical prostatectomy are used to treat stage III prostate cancer.[2] Prognosis is greatly affected by whether regional lymph nodes are evaluated and proven not to be involved. EBRT using a linear accelerator is the most common treatment for patients with stage III prostate cancer, and large series support its success in achieving local disease control and disease-free survival (DFS).[3,4] The results of radical prostatectomy in stage III patients are greatly inferior compared with results in patients with stage II cancer. Interstitial implantation of radioisotopes is

  10. Genetics of Prostate Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Identifying Genes and Inherited Variants Associated with Prostate Cancer Risk

    Various research methods have been employed to uncover the landscape of genetic variation associated with prostate cancer. Specific methodologies inform of unique phenotypes or inheritance patterns. The sections below describe prostate cancer research utilizing various methods to highlight their role in uncovering the genetic basis of prostate cancer. In an effort to identify disease susceptibility genes, linkage studies are typically performed on high-risk extended families in which multiple cases of a particular disease have occurred. Typically, gene mutations identified through linkage analyses are rare in the population, highly penetrant in families, and have large effect sizes. The

Displaying 51 - 60 of 212 Articles << Prev Page 2 3 4 5 6 7 8 9 10 11 Next >>

Today on WebMD

man with doctor
Symptoms, risks, treatments
man coughing
Men shouldn’t ignore
 
prostate cancer cells
What does this diagnosis mean?
doctor and male patient
Is it worth it?
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Men Ignore
FEATURE
 
Prostate Enlarged
VIDEO
Picture Of The Prostate
ANATOMY
 
Prostate Cancer Quiz
QUIZ
screening tests for men
SLIDESHOW
 
Prostate Cancer Symptoms
VIDEO
Vitamin D
SLIDESHOW